Public health. Rethinking influenza.
Rappuoli
Rino
R
Novartis Vaccines and Diagnostics Srl, 53100 Siena, Italy. rino.rappuoli@novartis.com
Del Giudice
Giuseppe
G
Nabel
Gary J
GJ
Osterhaus
Albert D M E
AD
Robinson
Robin
R
Salisbury
David
D
Stöhr
Klaus
K
Treanor
John J
JJ
D000276:Adjuvants, Immunologic; D000818:Animals; D000998:Antiviral Agents / Q000627:therapeutic use; D019049:Developed Countries; D003906:Developing Countries; D004196:Disease Outbreaks / Q000517:prevention & control; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology; D007252:Influenza Vaccines / Q000009:adverse effects / Q000276:immunology; D007251:Influenza, Human / Q000453:epidemiology / Q000517:prevention & control / Q000821:virology; D032541:Mass Vaccination; D009975:Orthomyxoviridae / Q000276:immunology; D011159:Population Surveillance
D000276:Adjuvants, Immunologic; D000998:Antiviral Agents; D007252:Influenza Vaccines